Search results
Results from the WOW.Com Content Network
A glycine reuptake inhibitor (GRI) is a type of drug which inhibits the reuptake of the neurotransmitter glycine by blocking one or more of the glycine transporters (GlyTs). ). Examples of GRIs include bitopertin (RG1678), iclepertin (BI-425809), ORG-24598, ORG-25935, ALX-5407, and sarcosine, which are selective GlyT1 blockers, and ORG-25435 and N-arachidonylglycine, which are selective GlyT2 blo
D-Phenylalanine (DPA, D-Phe; Deprenon, Sabiben, Sabiden) – enkephalinase inhibitor; Agomelatine (Valdoxan) – 5-HT 2C receptor antagonist and MT 1 and MT 2 receptor agonist; Brexanolone (allopregnanolone; Zulresso) – GABA A receptor positive allosteric modulator – approved for postpartum depression
Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1DAs, or incretin mimetics, [1] are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. They mimic the actions of the endogenous incretin hormone GLP-1, which is released by the gut after eating.
Sacubitril/valsartan, sold under the brand name Entresto among others, is a fixed-dose combination medication for use in heart failure.It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan.
Antiglucocorticoid drugs are a class of medications that act to reduce the effects of glucocorticoids, primarily cortisol, in the body. [1] They include direct glucocorticoid receptor antagonists such as mifepristone and synthesis inhibitors such as metyrapone, ketoconazole, and aminoglutethimide. They are used to treat Cushing's syndrome. [2]
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
DPP-4 inhibitors and GLP-1. Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins) are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2. The first agent of the class – sitagliptin – was approved by the FDA in 2006. [1]
Gemfibrozil, sold under the brand name Lopid among others, is a medication used to treat abnormal blood lipid levels. [3] It is generally less preferred than statins. [3] [4] Use is recommended together with dietary changes and exercise. [3]